The therapeutic promises of NAD+ boosters

Claudia Montllor-Albalate; Zehan Song; Danica Chen

doi:10.1016/j.cmet.2021.06.008

The therapeutic promises of NAD⁺ boosters

Cell Metab. 2021 Jul 6;33(7):1274-1275. doi: 10.1016/j.cmet.2021.06.008.

Authors

Claudia Montllor-Albalate¹, Zehan Song¹, Danica Chen²

Affiliations

¹ Program in Metabolic Biology, Nutritional Sciences & Toxicology, University of California, Berkeley, Berkeley, CA 94720, USA.
² Program in Metabolic Biology, Nutritional Sciences & Toxicology, University of California, Berkeley, Berkeley, CA 94720, USA. Electronic address: danicac@berkeley.edu.

PMID: 34233170
DOI: 10.1016/j.cmet.2021.06.008

Abstract

Numerous preclinical studies implicate the decline in NAD⁺ signaling in developing aging- and obesity-associated metabolic disorders. Yoshino et al. (2021) now provide the clinical evidence that an NAD⁺ booster increases muscle insulin sensitivity in postmenopausal prediabetic women, validating the therapeutic promises of NAD⁺ boosters in humans.

Publication types

Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Comment

MeSH terms

Aging
Female
Humans
Insulin Resistance*
Muscles
NAD
Prediabetic State*

Substances

NAD

Abstract

Publication types

MeSH terms

Substances

Grants and funding